{
    "Trade/Device Name(s)": [
        "DBIL Flex\u00ae reagent cartridge"
    ],
    "Submitter Information": "Dade Behring Inc.",
    "510(k) Number": "K061839",
    "Predicate Device Reference 510(k) Number(s)": [
        "k862359"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG"
    ],
    "Summary Letter Date": "August 29, 2006",
    "Summary Letter Received Date": "June 29, 2006",
    "Submission Date": "June 28, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Direct (conjugated) bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Dimension Vista\u2122 System"
    ],
    "Method(s)/Technology(ies)": [
        "Photometric (diazo chemistry)",
        "Bichromatic endpoint technique (540, 700 nm)"
    ],
    "Methodologies": [
        "Photometric",
        "Diazo chemistry"
    ],
    "Submission Type(s)": [
        "Reagent cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for DBIL Flex\u00ae reagent cartridge for quantitative measurement of direct (conjugated) bilirubin in serum and plasma using the Dimension Vista\u2122 System",
    "Indications for Use Summary": "In vitro diagnostic test for quantitative measurement of direct (conjugated) bilirubin in human serum and plasma to aid in diagnosis and treatment of liver, hemolytic, hematological and metabolic disorders including hepatitis and gall bladder disease",
    "fda_folder": "Clinical Chemistry"
}